The University of Cambridge and Life Technologies have formed a collaboration to advance translational research studies in key disease areas such as cancer, diabetes and neurological disorders. Through this collaboration, sequencing technology will be made available to the European research and clinical communities through the Eastern Sequence and Informatics Hub at Addenbrooke’s Hospital in Cambridge.
Genomics and biomedical scientists will use three SOLiD 3 Plus Systems, DNA sequencing platforms from Life Technologies, to advance targeted medical resequencing and whole transcriptome analysis research studies.
John Todd, professor and principal investigator at the Eastern Sequence and Informatics Hub, Addenbrooke’s Hospital, said: “We are at an exciting point in history where technologies such as the SOLiD System, provide the throughput and accuracy required for comprehensive characterisation of disease systems.
“The translation of this information into clinically relevant knowledge will have a direct impact on the treatment of human disease through the development of better diagnostic, prognostic and therapeutic agents.”
Shaf Yousaf, president of genomic analysis at Life Technologies, said: “The collaboration with the University of Cambridge’s Eastern Sequence and Informatics Hub, underlines our commitment to help deliver the potential of translational research and accelerate the realisation of personalised medicine.
“The SOLiD System offers an optimised and integrated next-generation sequencing solution to provide researchers with the required throughput, accuracy, speed and flexibility for a wide range of genetic investigations.”